Icon Plc $ICLR Stock Position Increased by Hudson Edge Investment Partners Inc.

Hudson Edge Investment Partners Inc. grew its position in shares of Icon Plc (NASDAQ:ICLR) by 12.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 200,739 shares of the medical research company’s stock after purchasing an additional 22,164 shares during the period. Icon makes up approximately 5.7% of Hudson Edge Investment Partners Inc.’s investment portfolio, making the stock its 5th biggest position. Hudson Edge Investment Partners Inc. owned 0.25% of Icon worth $35,129,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in ICLR. Private Trust Co. NA boosted its stake in Icon by 200.0% during the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after buying an additional 94 shares during the last quarter. Ameritas Advisory Services LLC purchased a new stake in shares of Icon during the 2nd quarter worth approximately $48,000. LRI Investments LLC bought a new position in shares of Icon during the 2nd quarter valued at approximately $49,000. Blue Trust Inc. grew its holdings in shares of Icon by 44.0% in the second quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock valued at $57,000 after purchasing an additional 120 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB increased its position in Icon by 153.4% in the third quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock worth $58,000 after purchasing an additional 201 shares during the last quarter. 95.61% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Barclays increased their price objective on shares of Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. Weiss Ratings restated a “hold (c)” rating on shares of Icon in a research report on Monday, December 29th. UBS Group set a $220.00 price target on Icon in a research report on Friday, October 24th. BMO Capital Markets initiated coverage on Icon in a research note on Thursday, November 13th. They set a “market perform” rating and a $175.00 price objective on the stock. Finally, Leerink Partners restated an “outperform” rating on shares of Icon in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat.com, Icon currently has an average rating of “Hold” and a consensus price target of $199.87.

Icon Trading Up 4.7%

Shares of NASDAQ ICLR opened at $184.87 on Thursday. Icon Plc has a fifty-two week low of $125.10 and a fifty-two week high of $211.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The company has a market cap of $14.93 billion, a price-to-earnings ratio of 25.02, a PEG ratio of 3.71 and a beta of 1.26. The business’s 50 day moving average price is $180.43 and its 200-day moving average price is $174.84.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.